BiotechTube
Altasciences

Altasciences

Laval, United States· Est.
altasciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $100M

Overview

Altasciences is a privately held, North American contract research organization (CRO) focused on the critical early phases of drug development, from preclinical through Phase II. The company provides an integrated suite of services including preclinical safety assessments, clinical pharmacology trials, bioanalysis, and manufacturing/analytical services, aiming to reduce program durations and improve decision-making for its clients. Under the leadership of CEO Marie-Hélène Raigneau, it emphasizes a 'moving in unison' approach, acting as an extension of sponsor teams to deliver personalized, efficient development pathways. Its value proposition centers on being a 'true one-stop-shop' that can streamline development and mitigate the traditional friction of using multiple vendors.

Drug DeliveryClinical Research

Technology Platform

Integrated service delivery model for early-phase drug development, combining in-house preclinical safety testing, clinical pharmacology, bioanalysis, and manufacturing/analytical services under one CRO to enable seamless, proactive program management.

Funding History

1
Total raised:$100M
Debt$100M

Opportunities

The growing trend of biopharma outsourcing, especially among virtual and small biotechs lacking internal capacity, creates sustained demand.
Increasing complexity of drug modalities (biologics, cell/gene therapies) requires specialized CRO expertise in bioanalysis and manufacturing, aligning with Altasciences' service offerings.
Industry pressure to reduce development timelines and costs plays directly into its value proposition of integrated, efficient early-phase development.

Risk Factors

Intense competition from both large global CROs and niche specialists could pressure pricing and client acquisition.
Revenue is tied to the cyclical R&D spending of biopharma clients, making it vulnerable to macroeconomic downturns or biotech funding contractions.
The core integrated model carries execution risk; any failure in coordination or quality between service divisions could damage its reputation and key differentiator.

Competitive Landscape

Altasciences competes in the fragmented CRO market, facing large, full-service public competitors like IQVIA, LabCorp, and Parexel, as well as other early-phase specialists. Its differentiation is its mid-size, integrated 'one-stop-shop' model for early development, emphasizing personal touch and seamless transitions between preclinical and clinical phases, in contrast to the scale of giants or the narrow focus of single-service vendors.

More companies in Digital Health & Biotech SaaS →More companies in United States →